Article
Oncology
Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane
Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran
Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou
Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yi Tat Tong, Zongshan Lai, Matthew H. G. Katz, Laura R. Prakash, Hua Wang, Deyali Chatterjee, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. E. Lee, Naruhiko Ikoma, Asif Rashid, Robert A. Wolff, Dan Zhao, Eugene J. Koay, Anirban Maitra, Huamin Wang
Summary: Our study examined the clinicopathologic factors and survival of 213 pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX and gemcitabine/nab-paclitaxel therapies. We found that FOLFIRINOX group had a better pathologic response and identified the tumor response group, ypN, ypT, LVI, and PNI as significant prognostic factors for survival.
Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
T. Y. S. Le Large, M. F. Bijlsma, B. El Hassouni, G. Mantini, T. Lagerweij, A. A. Henneman, N. Funel, B. Kok, T. Pham, R. de Haas, L. Morelli, J. C. Knol, S. R. Piersma, G. Kazemier, H. W. M. van Laarhoven, E. Giovannetti, C. R. Jimenez
Summary: In pancreatic ductal adenocarcinoma (PDAC), high activity of multiple receptor tyrosine kinases was observed, with the non-receptor kinase FAK identified as a potential target. Inhibition of FAK with defactinib reduced phosphorylation profiles, demonstrating anti-proliferative and anti-migratory effects. Combination therapy with (nab-)paclitaxel showed synergistic effects on cell proliferation and reduced tumor growth in PDAC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Zev A. Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R. Chandana, Christelle De La Fouchardiere, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O. Goetze, Eric Van Cutsem, A. Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A. Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M. O'Reilly
Summary: The study findings support the use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.
Article
Oncology
Iman M. Ahmad, Alicia J. Dafferner, Kelly A. O'Connell, Kamiya Mehla, Bradley E. Britigan, Michael A. Hollingsworth, Maher Y. Abdalla
Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Tumor hypoxia promotes tumor progression, malignancy, and therapy resistance in PDAC. The study demonstrates that nab-paclitaxel-gemcitabine (NPG) and a hypoxic tumor microenvironment up-regulate heme oxygenase-1 (HO-1), providing a survival advantage for tumors.
Article
Oncology
Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang, Chunmei Bai
Summary: This study compared the efficacy and safety of S-1 with gemcitabine plus nab-paclitaxel (GS) versus gemcitabine plus nab-paclitaxel (GnP) as first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC). The results showed that the GS regimen led to a significantly longer overall survival (OS) compared to the GnP regimen, while the progression-free survival (PFS), objective response rate (ORR), and incidence of severe adverse events were comparable between the GS and GnP groups.
CANCER BIOLOGY & MEDICINE
(2023)
Article
Oncology
Chen Chang, Xiaofen Li, Ke Cheng, Zhaolun Cai, Junjie Xiong, Wanrui Lv, Ruizhen Li, Pei Zhang, Dan Cao
Summary: The study evaluated the toxicity and feasibility of gemcitabine/nab-paclitaxel/S-1 (GAS) chemotherapy on a 21-day cycle in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results showed that GAS chemotherapy had acceptable toxicity and significant clinical control in these patients.
Article
Gastroenterology & Hepatology
Hiroyuki Asama, Makoto Ueno, Satoshi Kobayashi, Taito Fukushima, Kuniyuki Kawano, Yusuke Sano, Satoshi Tanaka, Shuhei Nagashima, Manabu Morimoto, Hiromasa Ohira, Shin Maeda
Summary: This study aimed to investigate the association between skeletal muscle mass and prognosis in unresectable PDAC patients treated with GnP. The results showed that sarcopenia was significantly associated with poor overall survival in elderly patients. However, there were no significant differences in progression-free survival or response rate between sarcopenia and non-sarcopenia patients.
Article
Gastroenterology & Hepatology
Flore Pignon, Anthony Turpin, Olivia Hentic, Romain Coriat, Emma Salmon, Isabelle Baumgaertner, Nicolas Bertrand, Philippe Levy, Vinciane Rebours, Pascal Hammel, Louis de Mestier
Summary: The study demonstrated that gemcitabine and nab-paclitaxel (GnP) treatment is well tolerated and effective in elderly patients with advanced pancreatic ductal adenocarcinoma. There was no significant difference in overall survival (OS) and progression-free survival (PFS) between patients aged <75 or >75 years, whether in the whole cohort or among those receiving GnP as first-line treatment.
Article
Oncology
Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella
Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Koh Fukushi, Akira Yamamiya, Keiichi Tominaga, Yoko Abe, Koki Hoshi, Kazunori Nagashima, Ken Kashima, Yasuhito Kunogi, Fumi Sakuma, Hidetsugu Yamagishi, Kazuyuki Ishida, Yasuo Haruyama, Atsushi Irisawa
Summary: The combined use of maspin staining and p53 staining showed high sensitivity and specificity in the diagnosis of pancreatic ductal adenocarcinoma (PDAC) using endoscopic ultrasound-guided puncture aspiration biopsy (EUS-FNA).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Yasunobu Yamashita, Kensuke Tanioka, Yuki Kawaji, Takashi Tamura, Junya Nuta, Keiichi Hatamaru, Masahiro Itonaga, Takeichi Yoshida, Yoshiyuki Ida, Takao Maekita, Mikitaka Iguchi, Masayuki Kitano
Article
Gastroenterology & Hepatology
Yasunobu Yamashita, Kensuke Tanioka, Yuki Kawaji, Takashi Tamura, Junya Nuta, Keiichi Hatamaru, Masahiro Itonaga, Yoshiyuki Ida, Takao Maekita, Mikitaka Iguchi, Masayuki Kitano
Summary: The study demonstrates that EUS-SWM method can serve as a precise tool for diagnosing chronic pancreatitis and determining exocrine/endocrine dysfunctions. EUS-SWM value is positively correlated with the Japan Pancreatic Society criteria stages, effectively distinguishing patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Editorial Material
Gastroenterology & Hepatology
Takashi Tamura, Yasunobu Yamashita, Yuki Kawaji, Keiichi Hatamaru, Masahiro Itonaga, Reiko Ashida, Ken-ichi Okada, Manabu Kawai, Hiroki Yamaue, Masayuki Kitano
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Takashi Tamura, Masahiro Itonaga, Reiko Ashida, Yasunobu Yamashita, Keiichi Hatamaru, Yuki Kawaji, Tomoya Emori, Yuji Kitahata, Motoki Miyazawa, Seiko Hirono, Ken-ichi Okada, Manabu Kawai, Toshio Shimokawa, Hiroki Yamaue, Masayuki Kitano
Summary: This study compared the effectiveness of FCSEMS and PS biliary stenting in preoperative drainage of BRPC patients, with results showing that FCSEMS had a lower rate of stent dysfunction, longer patency, and fewer re-interventions compared to PS.
DIGESTIVE ENDOSCOPY
(2021)
Article
Gastroenterology & Hepatology
Tomoya Emori, Junya Nuta, Yuki Kawaji, Takashi Tamura, Keiichi Hatamaru, Masahiro Itonaga, Yasunobu Yamashita, Reiko Ashida, Toshio Shimokawa, Masataka Koike, Akira Ikoma, Tetsuo Sonomura, Manabu Kawai, Masayuki Kitano
Summary: This study showed that EUS plus CH-EUS outperformed CE-CT and EUS alone in the accuracy of detecting left hepatic lobe metastases, especially for small hepatic metastases and accurate staging.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Tomoya Emori, Masahiro Itonaga, Reiko Ashida, Takashi Tamura, Yuki Kawaji, Keiichi Hatamaru, Yasunobu Yamashita, Toshio Shimokawa, Masataka Koike, Tetsuo Sonomura, Manabu Kawai, Masayuki Kitano
Summary: This study assessed the effects of sarcopenia on patients with pancreatic ductal adenocarcinoma (PDAC) undergoing chemotherapy. The results showed that sarcopenia had a negative impact on patients' progression-free survival and overall survival, and it was identified as an independent prognostic factor. In addition, the incidence of adverse events was significantly higher in the sarcopenia group.
Article
Medicine, General & Internal
Yasunobu Yamashita, Yuki Kawaji, Toshio Shimokawa, Hirofumi Yamazaki, Takashi Tamura, Keiichi Hatamaru, Masahiro Itonaga, Reiko Ashida, Manabu Kawai, Masayuki Kitano
Summary: This study aimed to evaluate the diagnostic value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) in malignant intraductal papillary mucinous neoplasms (IPMNs) and IPMN-associated invasive carcinoma (invasive IPMC). The results showed that CH-EUS had higher accuracy than contrast-enhanced computed tomography (CE-CT) and conventional EUS in detecting mural nodules and diagnosing malignant IPMN. Additionally, the vascular pattern on CH-EUS was useful for diagnosing invasive IPMC.
Article
Medicine, General & Internal
Takashi Tamura, Yuto Sugihara, Hirofumi Yamazaki, Hiromu Koutani, Takaaki Tamura, Ikuhisa Tsuda, Tomoya Emori, Yuki Kawaji, Keiichi Hatamaru, Yasunobu Yamashita, Masahiro Itonaga, Reiko Ashida, Masayuki Kitano
Summary: The purpose of this study is to investigate the associations between enhancement patterns on CH-EUS and the aggressiveness and prognosis of PanNENs. The late-phase vascular-poor pattern on CH-EUS showed the highest sensitivity and specificity for aggressive PanNENs. CH-EUS is valuable for the diagnosis and prognosis prediction of PanNENs.
Article
Medicine, General & Internal
Yasunobu Yamashita, Reiko Ashida, Hirofumi Yamazaki, Yuki Kawaji, Toshio Shimokawa, Takashi Tamura, Keiichi Hatamaru, Masahiro Itonaga, Masayuki Kitano
Summary: In EUS-TA for ≤ 2 cm SELs, the Fork-tip needle was superior to the Franseen needle in acquiring sufficient samples, and CH-EUS was also useful for the diagnosis of SELs.